The announcement from the WHO was looking, through their SAGE, which is their advisory mechanism, at HPV as a single-dose versus a two-dose and, in the past, even a three-dose vaccine for human papilloma virus and cervical cancer. It has nothing to do with COVID-19 in terms of where they are. They have suggested that data suggests, although it is not complete, that one dose of vaccine will give you protection for a period of time. They are unable to say at this time whether it will be a lifetime or not, but they feel that will be a more cost-effective way of working and, of course, people would be able to go back and revaccinate at a later time if necessary.
We will be following that WHO recommendation and therefore hopefully be able to accelerate the access to HPV vaccines.